vimarsana.com

Latest Breaking News On - Jean jacques bienaime - Page 3 : vimarsana.com

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Director Sells $1,632,400 00 in Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) Director Jean Jacques Bienaime sold 20,000 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $81.62, for a total transaction of $1,632,400.00. Following the transaction, the director now owns 474,994 shares in the company, valued […]

National Bank of Canada FI Cuts Stake in BioMarin Pharmaceutical Inc (NASDAQ:BMRN)

National Bank of Canada FI Cuts Stake in BioMarin Pharmaceutical Inc (NASDAQ:BMRN)
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Motley Fool Wealth Management LLC Reduces Holdings in BioMarin Pharmaceutical Inc (NASDAQ:BMRN)

Motley Fool Wealth Management LLC trimmed its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 3.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 470,289 shares of the biotechnology company’s stock after selling 18,667 shares during the period. BioMarin Pharmaceutical makes up about 2.4% of Motley Fool Wealth […]

Motley Fool Wealth Management LLC Sells 18,667 Shares of BioMarin Pharmaceutical Inc (NASDAQ:BMRN)

Motley Fool Wealth Management LLC reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 3.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 470,289 shares of the biotechnology company’s stock after selling 18,667 shares during the quarter. […]

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $112 00 at Morgan Stanley

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective decreased by Morgan Stanley from $115.00 to $112.00 in a research note released on Friday, Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock. Several other equities research analysts have also recently weighed in on the company. Cantor Fitzgerald reaffirmed […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.